2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Ephrin Receptor
  5. EphA Isoform

EphA

 

EphA Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-133178
    Urolithin D
    		Antagonist 99.72%
    Urolithin D (3,4,8,9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC50 of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases.
  • HY-P11015
    (123B9)2-Motif
    		Agonist
    (123B9)2-Motif is a selective EphA2 receptor agonist (Kd=4.9 μM) that does not bind to EphA4. (123B9)2-Motif works by inducing EphA2 receptor phosphorylation and oligomerization, thereby promoting receptor activation and internalization. (123B9)2-Motif is primarily used in targeted drug delivery studies for cancers that overexpress EphA2, such as breast cancer, to reduce circulating tumor cells and inhibit metastasis.
  • HY-P11018
    (123B9)2-L2-PTX
    		Agonist
    (123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers.